Mark Orgel, MD
Family Medicine · North Augusta, SCNPI 1902912157
Payments from drug & device makers
Across 204 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$630
- Lilly USA, LLC$579
- Novo Nordisk$427
- Abbott$268
- AstraZeneca$252
- Exact Sciences$155
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,322100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $630 |
| Lilly USA, LLC | 34 | $579 |
| Novo Nordisk | 24 | $427 |
| Abbott | 14 | $268 |
| AstraZeneca | 16 | $252 |
| Exact Sciences | 7 | $155 |
| GSK | 10 | $152 |
| Pfizer | 10 | $136 |
| Boehringer Ingelheim | 8 | $133 |
| Amgen | 8 | $129 |
| Idorsia Pharmaceuticals US Inc | 6 | $99 |
| Genentech USA, Inc. | 6 | $97 |
| Edwards Lifesciences | 1 | $28 |
| Boston Scientific | 1 | $26 |
| Dexcom, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Novartis | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$3,322 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $145,927 |
| MounjaroTirzepatide | 77 | $112,446 |
| TrulicityDulaglutide | 59 | $102,655 |
| JardianceEmpagliflozin | 82 | $94,186 |
| OzempicSemaglutide | 46 | $74,405 |
| JanuviaSitagliptin Phosphate | 33 | $40,953 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $34,718 |
| FarxigaDapagliflozin Propanediol | 42 | $31,449 |
| XareltoRivaroxaban | 27 | $26,200 |
| MyrbetriqMirabegron | 22 | $22,559 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $16,032 |
| Atorvastatin Calcium | 839 | $8,345 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,435 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $6,982 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $579 | $215,102136 claims |
| PfizerEliquis | $136 | $145,927125 claims |
| Boehringer IngelheimJardiance | $133 | $94,18682 claims |
| Novo NordiskOzempic | $427 | $74,40546 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $152 | $50,75054 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $252 | $45,86673 claims |
| MerckJanuvia, Dulera | $19 | $44,65844 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $22,55922 claims |
| AbbVieSynthroid | $630 | $3,04355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in North Augusta
- Jeffrey BroderNorth Augusta$140K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.